Printer Friendly

A.L. LABORATORIES REPORTS SECOND QUARTER AND SIX MONTHS RESULTS

 A.L. LABORATORIES REPORTS SECOND QUARTER AND SIX MONTHS RESULTS
 FORT LEE, N.J., July 31 /PRNewswire/ -- A.L. Laboratories, Inc. (NYSE: BMD) today reported that for its second quarter ended June 30, 1992, total revenue from continuing operations increased 17 percent to $70,412,000 compared with $60,100,000 in 1991. Net income from continuing operations increased 19 percent to $2,923,000 from $2,457,000 in the second quarter last year. Fully diluted per share earnings from continuing operations rose to $.17 compared with $.15 in the same period of 1991.
 Total revenue from continuing operations for the six months ended June 30, 1992 increased 15 percent to $141,628,000 compared with $123,206,000 in 1991. Net income from continuing operations for increased 35 percent to $6,491,000 from $4,813,000, in the first half of 1991. Fully diluted per share earnings from continuing operations increased to $.37 from $.29 in the comparable period of 1991.
 The results of the company's Human Nutrition business are being reported as a discontinued operation due to the impending divestiture of the low-margin business segment.
 For the second quarter ended June 30, 1992, net income from discontinued operations was $386,000 or $.02 per share, as compared with $271,000 or $.01 in 1991. Net income from discontinued operations for the first half of 1992 was $774,000 or $.04 per share compared to $2,219,000 or $.11 per share in the comparable period of 1991, which includes income recorded in the first quarter of 1991 related to the sale of certain trademarks pertaining to the company's European-based Human Nutrition business.
 A.L. Laboratories is a multinational manufacturer and marketer of specialized value-added, branded pharmaceuticals and animal health micronutrients, with plant sites in Chicago Heights, Ill., Niagara Falls and Glendale, N.Y.; Baltimore; Bellevue, Wash.; Copenhagen, Denmark; and Jakarta, Indonesia.
 A.L. LABORATORIES, INC.
 Consolidated Statement of Income
 (Unaudited)
 Periods ended Three Months Six Months
 June 30 1992 1991(A) 1992 1991(A)
 Total revenue 70,412 60,100 141,628 123,206
 Cost of sales 38,754 31,915 77,710 65,719
 Gross profit 31,658 28,185 63,918 57,487
 S,G&A expenses 23,708 21,166 47,086 42,903
 Operating income 7,950 7,019 16,832 14,584
 Interest expense (2,892) (2,909) (5,963) (5,942)
 Other, net (124) (1) 112 128
 Inc. from cont. opers.
 before provision
 for inc. taxes 4,934 4,109 10,981 8,770
 Provision for
 income taxes 2,011 1,652 4,490 3,957
 Inc. for cont. opers. 2,923 2,457 6,491 4,813
 Inc. from discont.
 opers., net of tax 386 271 774 2,219
 Net income $3,309 $2,728 $7,265 $7,032
 Average common shares
 outstanding:
 Primary 17,108 16,882 17,098 16,870
 Fully diluted 21,549 21,482 21,541 21,473
 Earnings Per Common
 Share(C):
 Primary
 Inc. from cont. opers. $.17 $.15 $.38 $.29
 Net income .19 .16 .42 .42
 Fully Diluted
 Inc. from cont. opers. $.17 $.15 $.37 $.29
 Net income .19 .16 .41 .40
 Dividend per common share $.045 $.04 $.09 $.08
 (A) -- Restated to reflect the Human Nutrition business as a discontinued operation.
 A.L. LABORATORIES, INC.
 Financial Position
 (In thousands)
 6/30/92 12/31/91
 (Unaudited) (Audited)
 Current assets $141,065 $159,540
 Non-current assets 197,347 199,290
 Total assets 338,412 358,830
 Current liabilities 82,883 105,720
 Long-term debt:
 Senior 54,725 59,197
 7-3/4 percent
 subord. convertible
 debentures 59,503 60,197
 Deferred taxes and
 other liabilities 20,220 19,710
 Stockholders' equity 121,081 114,006
 Total liabilities and
 stockholders' equity 338,412 358,830
 -0- 7/31/92
 /CONTACT: Iris D. Daniels, investor relations manager of A. L. Laboratories, 201-947-7774, or David Walke of Morgen-Walke Associates, 212-986-5900, for A.L. Laboratories/
 (BMD) CO: A.L. Laboratories, Inc. ST: New Jersey IN: MTC SU: ERN


TS-SM -- NY006 -- 5442 07/31/92 08:46 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 31, 1992
Words:679
Previous Article:QUARTERLY CONDO SALES REMAIN HEALTHY
Next Article:RATNERS GROUP TO PUBLISH ACCOUNTS FOLLOWING NEGOTIATIONS WITH LENDERS
Topics:


Related Articles
INTERPHARM LABORATORIES LTD. REPORTS EARNINGS AND INCOME FOR THE SECOND QUARTER OF 1992
ROYCE LABORATORIES ANNOUNCES SECOND QUARTER AND SIX MONTH RESULTS
COLUMBIA LABORATORIES REPORTS SECOND QUARTER SALES INCREASE 24 PERCENT AND NET LOSS DECREASES 51 PERCENT
FOREST LABORATORIES REPORTS RECORD FISCAL SECOND QUARTER RESULTS
ABBOTT REPORTS INCREASE IN SALES, EARNINGS IN SECOND QUARTER; EARNINGS PER SHARE UP 13.5 PERCENT
FOREST LABORATORIES REPORTS RECORD FISCAL SECOND QUARTER RESULTS
GENSIA REPORTS 1994 SECOND QUARTER RESULTS
BARR REPORTS DOUBLE DIGIT INCREASES FOR SECOND QUARTER SALES AND EARNINGS; FIFTH CONSECUTIVE QUARTER OF GROWTH
DEL LABORATORIES, INC. REPORTS SECOND QUARTER RESULTS
Del Laboratories Announces Second Quarter and First Half Results

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters